Ratner Lab

Publications

Largaespada, D; Williams, K; Larsson, A; Keller, B; Stehn, C; Chaney, K; Williams, R; Bhunia, M; Draper, G; Jubenville, T; Hudson, W; Galvin, R; Moertel, C; Ratner, N. DDDR-42. Modeling and Translating Precision Therapies for NF1-Associated Tumors Across the Disease Spectrum. Neuro-Oncology. 2025; 27(Supplement_5):v172-v172.

Williams, KB; Larsson, AT; Keller, BJ; Chaney, KE; Williams, RL; Bhunia, MM; Draper, GM; Jubenville, TA; Hudson, WA; Georg, GI; Moertel, CL; Ratner, N; Largaespada, DA. Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors. Molecular Cancer Therapeutics. 2025.

Raut, N; Adlakha, A; Sprague, KL; Rupert, AR; Hofmann, M; Ratner, N; Queme, LF; Jankowski, M. 137 Schwann Cell Glial Cell Line-Derived Neurotrophic Factor Signaling Influences Pain in Neurofibromatosis 1. Journal of Pain. 2025; 29:104935.

Lucas, C-HG; Gross, AM; Romo, CG; Dehner, CA; Lazar, AJ; Miettinen, M; Pekmezci, M; Quezado, M; Rodriguez, FJ; Stemmer-Rachamimov, A; Viskochil, D; Perry, A. Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis Type 1. Neuro-Oncology. 2025; 27(3):616-624.

Ahmari, N; Choi, K; Wu, J; Rizvi, TA; Jackson, M; Kershner, LJ; Kim, M-O; Zhang, X; Dombi, E; Shern, J; Hildeman, DA; Ratner, N. Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas. Life Science Alliance. 2025; 8(12).

Pundavela, J; Hall, A; Dinglasan, SA; Choi, K; Rizvi, TA; Trapnell, BC; Wu, J; Ratner, N. Granulocyte-Macrophage Colony Stimulating Factor Receptor Contributes to Plexiform Neurofibroma Initiation. Cancers. 2025; 17(5).

Pundavela, J; Dinglasan, SA; Touvron, M; Hummel, SA; Hu, L; Rizvi, TA; Choi, K; Hildeman, DA; Ratner, N. Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance. Science Advances. 2024; 10(42):eado6342.

Patritti-Cram, J; Rahrmann, EP; Rizvi, TA; Scheffer, KC; Phoenix, TN; Largaespada, DA; Ratner, N. NF1-dependent disruption of the blood-nerve-barrier is improved by blockade of P2RY14. iScience. 2024; 27(7):110294.

Raut, NG; Maile, LA; Oswalt, LM; Mitxelena, I; Adlakha, A; Sprague, KL; Rupert, AR; Bokros, L; Hofmann, MC; Patritti-Cram, J; Rizvi, TA; Queme, LF; Choi, K; Ratner, N; Jankowski, MP. Schwann cells modulate nociception in neurofibromatosis 1. JCI Insight. 2024; 9(2).

Paudel, SN; Hutzen, BJ; Miller, KE; Garfinkle, EAR; Chen, C-Y; Wang, P-Y; Glaspell, AM; Currier, MA; Ringwalt, EM; Boon, L; Ratner, N; Dodd, RD; Cassady, KA; Cripe, TP. Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors. Frontiers in Immunology. 2024; 15:1384623.

Perrino, MR; Ahmari, N; Hall, A; Jackson, M; Na, Y; Pundavela, J; Szabo, S; Woodruff, TM; Dombi, E; Kim, M-O; Köhl, J; Wu, J; Ratner, N. C5aR plus MEK inhibition durably targets the tumor milieu and reveals tumor cell phagocytosis. Life Science Alliance. 2024; 7(5).

Wu, J; Ratner, N. Neurofibromatosis Type I: Preclinical Modeling. In: The RASopathies. Springer Nature; 2024:855-868.

Pillay-Smiley, N; Fletcher, JS; De Blank, P; Ratner, N. Shedding New Light: Novel Therapies for Common Disorders in Children with Neurofibromatosis Type I. Pediatric Clinics of North America. 2023; 70(5):937-950.

González-Muñoz, T; Di Giannatale, A; García-Silva, S; Santos, V; Sánchez-Redondo, S; Savini, C; Graña-Castro, O; Blanco-Aparicio, C; Fischer, S; De Wever, O; Ratner, N; Yohay, K; Theuer, CP; Peinado, H. Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis. Clinical Cancer Research. 2023; 29(18):3744-3758.

Doherty, AC; Huddleston, DA; Horn, PS; Ratner, N; Simpson, BN; Schorry, EK; Aschbacher-Smith, L; Prada, CE; Gilbert, DL. Motor Function and Physiology in Youth With Neurofibromatosis Type 1. Pediatric Neurology. 2023; 143:34-43.

Ratner, N; Hu, L; Pundavela, J; Epstein, JA. Abstract IA17: Use of RAS isoforms in nerve tumors. Molecular Cancer Research. 2023; 21(5_Supplement):ia17-ia17.

Magallón-Lorenz, M; Terribas, E; Ortega-Bertran, S; Creus-Bachiller, E; Fernández, M; Requena, G; Rosas, I; Mazuelas, H; Uriarte-Arrazola, I; Negro, A; Reuss, D; Carrió, M; Gel, B; Serra, E. Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis. iScience. 2023; 26(2):106096.

Hennigan, RF; Thomson, CS; Stachowski, K; Nassar, N; Ratner, N. Merlin tumor suppressor function is regulated by PIP2-mediated dimerization. PLoS ONE. 2023; 18(2):e0281876.

Wang, C; Tu, Z; Cai, X; Wang, W; Davis, AK; Nattamai, K; Paranjpe, A; Dexheimer, P; Wu, J; Huang, FL; Geiger, H; Huang, G; Zheng, Y. A critical role of RUNX1 in governing megakaryocyte-primed hematopoietic stem cell differentiation. Blood advances. 2023; 7(11):2590-2605.

Jackson, M; Ahmari, N; Wu, J; Rizvi, TA; Fugate, E; Kim, M-O; Dombi, E; Arnhof, H; Boehmelt, G; Düchs, MJ; Long, CJ; Maier, U; Trapani, F; Hofmann, MH; Ratner, N. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. Journal of Pharmacology and Experimental Therapeutics. 2023; 385(2):106-116.

Na, Y; Hall, A; Yu, Y; Hu, L; Choi, K; Burgard, JA; Szabo, S; Huang, G; Ratner, N; Wu, J. Runx1/3-driven adaptive endoplasmic reticulum stress pathways contribute to neurofibromagenesis. Oncogene. 2023; 42(13):1038-1047.

González-Muñoz, T; Kim, A; Ratner, N; Peinado, H. The Need for New Treatments Targeting MPNST: The Potential of Strategies Combining MEK Inhibitors with Antiangiogenic Agents. Clinical Cancer Research. 2022; 28(15):3185-3195.

Kershner, LJ; Choi, K; Wu, J; Zhang, X; Perrino, M; Salomonis, N; Shern, JF; Ratner, N. Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment. JCI Insight. 2022; 7(18).

Patritti Cram, J; Wu, J; Coover, RA; Rizvi, TA; Chaney, KE; Ravindran, R; Cancelas, JA; Spinner, RJ; Ratner, N. P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis. eLife. 2022; 11.

Heinrich, A; Bhandary, B; Potter, SJ; Ratner, N; Defalco, T. Cdc42 activity in Sertoli cells is essential for maintenance of spermatogenesis. Cell reports. 2021; 37(4):109885.

Patritti-Cram, J; Coover, RA; Jankowski, MP; Ratner, N. Purinergic signaling in peripheral nervous system glial cells. Glia. 2021; 69(8):1837-1851.

Thomson, CS; Pundavela, J; Perrino, MR; Coover, RA; Choi, K; Chaney, KE; Rizvi, TA; Largaespada, DA; Ratner, N. WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth. Oncogene. 2021; 40(24):4229-4241.

Vélez-Reyes, GL; Koes, N; Ryu, JH; Kaufmann, G; Berner, M; Weg, MT; Wolf, NK; Rathe, SK; Ratner, N; Moriarity, BS; Largaespada, DA. Transposon Mutagenesis-Guided CRISPR/Cas9 Screening Strongly Implicates Dysregulation of Hippo/YAP Signaling in Malignant Peripheral Nerve Sheath Tumor Development. Cancers. 2021; 13(7).

Galvin, R; Watson, AL; Largaespada, DA; Ratner, N; Osum, S; Moertel, CL. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. Current Oncology Reports. 2021; 23(4):45.

Weiss, BD; Wolters, PL; Plotkin, SR; Widemann, BC; Tonsgard, JH; Blakeley, J; Allen, JC; Schorry, E; Korf, B; Robison, NJ; Dombi, E; Ratner, N; Packer, R; Fisher, MJ. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Journal of Clinical Oncology. 2021; 39(7):797-806.

Oatman, N; Dasgupta, N; Arora, P; Choi, K; Gawali, MV; Gupta, N; Parameswaran, S; Salomone, J; Reisz, JA; Lawler, S; Weirauch, MT; D'alessandro, A; Komurov, K; Dasgupta, B. Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. Science Advances. 2021; 7(7).

Na, Y; Hall, A; Choi, K; Hu, L; Rose, J; Coover, RA; Miller, A; Hennigan, RF; Dombi, E; Kim, M-O; Subramanian, S; Ratner, N; Wu, J. MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK. Oncogene. 2021; 40(5):951-963.